SugarCone Biotech

MARCH 24, 2025

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Other mechanisms that cancer cells use to escape from TCE treatment are less expected. Today, however, we turn to the TCE therapeutic class.

Immune Response 64

Immune Response Therapies Treatment Disease 64

Chemical Biology and Drug Design

JANUARY 29, 2024

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

Drug Target Review

NOVEMBER 24, 2023

La-Beck explained: “The thing that’s really attractive with using a nanoparticle in cancer treatments is that the nanoparticle is much larger than chemotherapy molecules.” Doxorubicin, a drug frequently used for breast cancer treatment, causes significant heart toxicity. On the other hand, some of these responses were bad.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? This combination approach resulted in durable anti-tumour T cell responses and tumour eradication. It may also overcome resistance mechanisms developed by tumours to evade the immune response over time.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

Chemical Biology and Drug Design

APRIL 28, 2023

Leishmania infection may arise from virulence factors; they are treatable with medications or vaccinations more promptly and might greatly shorten the duration of treatment.

Immune Response 100

Immune Response Vaccine Treatment Disease 100

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 87

Immune Response Production Regulations Clinical Trials 87

The Pharma Data

OCTOBER 6, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

DrugBank

MARCH 12, 2025

  The Expanding Role of mRNA in Cancer Therapy One of the most exciting applications of mRNA therapeutics lies in cancer treatment, where leveraging the immune system to target tumors offers a novel approach. This process triggers a robust immune response, enabling the immune system to recognize and attack cancer cells.

Vaccine 52

Vaccine Treatment Clinical Trials Therapies 52

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

Drug Target Review

OCTOBER 19, 2023

Scientists at the University of California, San Francisco (UCSF) have been exploring this question, and their recent breakthrough will focus on the treatment of conditions such as eczema and allergies. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.

RNA 128

RNA Immune Response Therapies Disease 128

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response.

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

JANUARY 15, 2024

Monoclonal antibodies (mAbs) targeting tumour-specific antigens play an essential role in the treatment of many cancers. An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

SEPTEMBER 9, 2024

functions to reset the immune system and potentially provide remission for allergic diseases? 1104 acts upstream in the inflammatory response, targeting one of the first key players: antigen-presenting cells (APCs). In allergic diseases, APCs identify and present unknown antigens to the immune system.

Disease 64

Disease Immune Response Clinical Trials Treatment 64

Drug Target Review

JUNE 6, 2023

In this IO arena, we continue to search for additional treatments that can further benefit patients. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

SEPTEMBER 8, 2021

in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). 1 Given the overall poor prognosis for this patient subset, there is an urgent need for novel treatment options,” 2 said lead author Suresh S. Reese, M.D., Ramalingam, M.D.,

Trials 52

Trials Clinical Trials Therapies Treatment 52

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. 1 Lung transplantation is the only viable treatment option, yet finding suitable lung donors is difficult.

Immune Response 113

Immune Response Disease Science Therapies 113

DrugBank

MAY 6, 2024

Unlike conventional chemical-based medicines, biologics offer targeted therapies derived from living cells, which can result in more effective and personalized treatments. This surge in approvals clearly marks a new era in healthcare, emphasizing the rapid progress and heightened focus on biologics in medical treatment.

FDA Approval 96

FDA Approval Therapies Treatment Clinical Trials 96

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

MARCH 9, 2021

Novartis and CANOPY-2 investigators will analyze the study data and are expected to submit its findings for presentation at an upcoming medical meeting. Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings. Canakinumab is a first-in-class interleukin-1beta (IL-1?)

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

PLOS: DNA Science

OCTOBER 12, 2023

Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases. Can they deliver healing genes without triggering an overactive immune response? That left a more immediate and generalized innate immune response as the likely culprit.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

MAY 14, 2024

How do hydrophobicity, electrostatic charge, and secondary confirmation of helical polypeptides influence the stimulation of innate immune pathways in antigen-presenting cells (APCs)? How did the combination of the polypeptides with immune checkpoint inhibitors affect the antitumour responses in the mouse models?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Olympian Clinical Research

NOVEMBER 16, 2022

In its early stages, HS often presents as a small, pea-sized lump in one place. HS is believed to develop due to an immune response that generates too much inflammation. People with HS may have an overactive immune system, which causes their bodies to overreact to the presence of a blocked hair follicle. Heal breakouts.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

Drug Target Review

DECEMBER 13, 2023

This is likely indicative of the heterogeneous nature of the disorder, and it is this complexity and diversity of clinical presentation and effects across multiple organ systems, that has made efforts to identify genetic risk factors using traditional genomic analysis approaches extremely challenging.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. SAN CARLOS, Calif. ,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

The Pharma Data

MARCH 29, 2022

Application based on CheckMate -816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete response with an immunotherapy-based combination in the neoadjuvant setting of NSCLC. Opdivo -based treatments have shown clinical benefit in four Phase 3 trials in earlier stages of cancer.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

Conversations in Drug Development Trends

MARCH 12, 2024

From their use in risk and safety assessments to patient screening and treatment efficacy, biomarkers offer minimally invasive, objective data. Deviations from established baseline values provide insights into treatment response in certain cancer indications. Currently, there are thousands of known biomarkers.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

APRIL 16, 2021

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib. vice president, development program lead, genitourinary cancers, Bristol Myers Squibb.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. Three neutralized the virus even when present at extremely low levels, and they now will be studied further as possible monoclonal antibodies. But again, not all antibodies are created equal.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

AUGUST 17, 2021

Results from CheckMate -648 were presented in an oral session during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were selected for the official ASCO press program. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52